Lead Product(s) : XVR012,XVR014
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ExeVir Bio Reveals Positive Virus Neutralization Data for XVR012 Against Omicron Variants
Details : XVR012 is a cocktail of XVR013m and XVR014, targets three distinct epitopes. It is currently being evaluated in preclinical studies for the treatment of Covid-19 infection.
Product Name : XVR012
Product Type : Antibody
Upfront Cash : Inapplicable
January 15, 2024
Lead Product(s) : XVR012,XVR014
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $3.2 million
Deal Type : Funding
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
Details : The grant will be used to advance AstriVax’ candidate CHB therapeutic vaccine in clinical development for the treatment of chronic Hepatitis B. It efficiently induces specific CD8+ T-cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $3.2 million
Deal Type : Funding
Lead Product(s) : XVR012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
ExeVir Bio Secures EUR 25 Million Venture Debt Financing from The European Investment Bank
Details : The EIB financing will help to advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19. XVR012, is a potent COVID-19 neutralizing antibody that targets the S1 and S2 region of the coronavirus.
Product Name : XVR012
Product Type : Antibody
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : XVR012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : XVR021
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.7 million
Deal Type : Funding
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
Details : The funding will be used by ExeVir for pre-clinical research towards prophylactic and therapeutic solutions including, XVR021 for dengue by leveraging its unique, modular llama-derived antibody (VHH) technology platform to generate multi-specific antibod...
Product Name : XVR021
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : XVR021
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : XVR013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : VIB
Deal Size : Inapplicable
Deal Type : Inapplicable
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
Details : XVR013 targets a conserved region in the spike S2 subunit that is essential for viral entry. It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.
Product Name : XVR013
Product Type : Vaccine
Upfront Cash : Inapplicable
March 13, 2023
Lead Product(s) : XVR013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : VIB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RSV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Anima Research Center Participating In A Trial For An Investigational RSV Vaccine
Details : Anima is collaborating with the U.S. pharmaceutical company Moderna, among others, to evaluate an RSV vaccine under development, aimed at persons over 60 years of age.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : RSV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZIP-1642
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
Details : Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features.
Product Name : ZIP-1642
Product Type : Vaccine
Upfront Cash : Undisclosed
June 23, 2022
Lead Product(s) : ZIP-1642
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : FINCoVac 2.0
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Rokote Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Details : The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other ...
Product Name : FINCoVac 2.0
Product Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : FINCoVac 2.0
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Rokote Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : CVXGA1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Cyanvac
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Exothera will be responsible for the fast-track development of a manufacturing process for CyanVac’s COVID-19 vaccine candidate, CVXGA1, using the unique scale-X™ platform.
Product Name : CVXGA1
Product Type : Vaccine
Upfront Cash : Undisclosed
March 24, 2021
Lead Product(s) : CVXGA1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Cyanvac
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VHH72-FC
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $27.1 million
Deal Type : Series A Financing
ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19
Details : Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell.
Product Name : VHH72-FC
Product Type : Antibody
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : VHH72-FC
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $27.1 million
Deal Type : Series A Financing